Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya & Anthony H. Barnett. (2009) DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine 121:6, pages 70-100.
Read now
Read now
F. Xavier Pi-Sunyer. (2009) The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. Postgraduate Medicine 121:5, pages 94-107.
Read now
Read now
Articles from other publishers (40)
Eiji Kutoh, Alexandra N. Kuto, Eri Ozawa, Rumi Kurihara & Midori Akiyama. (2023) Regulation of Adipose Tissue Insulin Resistance and Diabetic
Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with
Canagliflozin Monotherapy. Drug Research 73:05, pages 279-288.
Crossref
Crossref
José Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, María Teresa Pérez-Álvarez, Belén Ponce-Piñón, Marlén Fernández-Silva, Marta Rodríguez-Barreiro, Mercedes Pereira-Pía, Jose Manuel Iglesias-Moreno, Mar Gago-García, Raquel Montáns-García, Agustina Fernandez-Perez, Dolores FragaGayoso, Montse Fernandez-Montenegro, Beatriz Riveiro-Barciela, Natalia Rilla-Villar, Alberto Cordero, Moisés RodríguezMañero & José R. González-Juanatey. (2023) Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase. Primary Care Diabetes.
Crossref
Crossref
Yousef Alhindi & Amanda Avery. (2022) The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis. Contemporary Clinical Trials Communications 28, pages 100944.
Crossref
Crossref
Fu-ping Lyu, Bing-kun Huang, Wei-juan Su, Fang-fang Yan, Jin-yang Zeng, Zheng Chen, Yu-xian Zhang, Shun-hua Wang, Yin-xiang Huang, Mu-lin Zhang, Xiu-lin Shi, Ming-zhu Lin & Xue-jun Li. (2020) Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes. Diabetes Therapy 11:3, pages 701-710.
Crossref
Crossref
N. M. Aldekhail, D. S. Morrison, H. Khojah, B. Sloan, P. McLoone, S. MacNaughton, R. Shearer & J. Logue. (2019) The association between diabetes medication and weight change in a non‐surgical weight management intervention: an intervention cohort study. Diabetic Medicine 37:2, pages 248-255.
Crossref
Crossref
Anand S. Nair, Debasis Bagchi, Teresa E. Lehmann & Sreejayan Nair. 2018. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
207
214
.
Mingxing Li, Yi Yang, Deqi Jiang, Miaofa Ying, Yong Wang & Rui Zhao. (2017) Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes. Medicine 96:39, pages e8161.
Crossref
Crossref
Xiaoling Cai, Liwei Ji, Yifei Chen, Wenjia Yang, Lingli Zhou, Xueyao Han, Simin Zhang & Linong Ji. (2017) Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. Journal of Diabetes Investigation 8:4, pages 510-517.
Crossref
Crossref
R Ravi Shankar, Yuqian Bao, Ping Han, Ji Hu, Jianhua Ma, Yongde Peng, Fan Wu, Lei Xu, Samuel S Engel & Weiping Jia. (2017) Sitagliptin added to stable insulin therapy with or without metformin in Chinese patients with type 2 diabetes. Journal of Diabetes Investigation 8:3, pages 321-329.
Crossref
Crossref
Naoko Tajima, Takashi Kadowaki, Masato Odawara, Toshiomi Minamide, Akiteru Seki, Kaori Oki, Reiko Nagayasu & Juan Camilo Arjona Ferreira. (2015) Safety and efficacy of addition of sitagliptin to rapid-acting insulin secretagogues for glycemic control, including post-prandial hyperglycemia, among Japanese with type 2 diabetes mellitus. Diabetology International 7:2, pages 155-166.
Crossref
Crossref
Carla Lubrano, Lucio Gnessi & Silvia Migliaccio. 2015. Multidisciplinary Approach to Obesity. Multidisciplinary Approach to Obesity
73
82
.
Magdalena Pasarica & Steven R. Smith. 2014. Treatment of the Obese Patient. Treatment of the Obese Patient
225
245
.
Magdalena Pasarica & Steven R. Smith. 2014. Treatment of the Obese Patient. Treatment of the Obese Patient
225
245
.
Takashi Kadowaki, Naoko Tajima, Masato Odawara, Toshiomi Minamide, Masaru Kawashima, Daisuke Yanagida, Taro Okamoto & Juan Camilo Arjona Ferreira. (2013) Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetology International 4:3, pages 160-172.
Crossref
Crossref
I. El-Sayes, R. Weiner, M. Talai Rad, S. Wolff, C. Knoll, T. Manger & C. Stroh. (2013) Amelioration of Diabetes Mellitus Type II after Sleeve Gastrectomy—Data on Nationwide Survey on Quality Assurance in Bariatric Surgery in Germany. Surgical Science 04:12, pages 8-12.
Crossref
Crossref
Seiya Shimoda, Shinsuke Iwashita, Shinji Ichimori, Yasuto Matsuo, Rieko Goto, Takako Maeda, Tomoko Matsuo, Taiji Sekigami, Junji Kawashima, Tatsuya Kondo, Takeshi Matsumura, Hiroyuki Motoshima, Noboru Furukawa, Kenro Nishida & Eiichi Araki. (2013) Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy. Endocrine Journal 60:10, pages 1207-1214.
Crossref
Crossref
E. S. Hong, A. R. Khang, J. W. Yoon, S. M. Kang, S. H. Choi, K. S. Park, H. C. Jang, H. Shin, G. A. Walford & S. Lim. (2012) Comparison between sitagliptin as add‐on therapy to insulin and insulin dose‐increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes, Obesity and Metabolism 14:9, pages 795-802.
Crossref
Crossref
Christian Hölscher. 2012. Therapeutic Targets. Therapeutic Targets
351
373
.
Richard B. Aguilar. (2011) Evaluating Treatment Algorithms for the Management of Patients With Type 2 Diabetes Mellitus: A Perspective on the Definition of Treatment Success. Clinical Therapeutics 33:4, pages 408-424.
Crossref
Crossref
Fernando Ovalle. (2011) Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes. Clinical Therapeutics 33:4, pages 393-407.
Crossref
Crossref
Yehuda Handelsman, Jeffrey I. Mechanick, Lawrence Blonde, George Grunberger, Zachary T. Bloomgarden, George A. Bray, Samuel Dagogo-Jack, Jaime A. Davidson, Daniel Einhorn, Om Ganda, Alan J. Garber, Irl B. Hirsch, Edward S. Horton, Faramarz Ismail-Beigi, Paul S. Jellinger, Kenneth L. Jones, Lois Jovanovič, Harold Lebovitz, Philip Levy, Etie S. Moghissi, Eric A. Orzeck, Aaron I. Vinik, Kathleen L. Wyne, Alan J. Garber, Daniel L. Hurley & Farhad Zangeneh. (2011) American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice 17, pages 1-53.
Crossref
Crossref
Chidambarann SudhakaranUtkal KishoreRanjit Mohan AnjanaRanjit UnnikrishnanViswanathan Mohan. (2011) Effectiveness of Sitagliptin in Asian Indian Patients with Type 2 Diabetes—An Indian Tertiary Diabetes Care Center Experience. Diabetes Technology & Therapeutics 13:1, pages 27-32.
Crossref
Crossref
A. Pietrobelli, C. Tosi, E. Kapantais, G. Rayner & I. Kaklamanos. (2010) Obesity and diabetes: never say never again!. Diabetes, Obesity and Metabolism 12:10, pages 835-837.
Crossref
Crossref
Pablo B. Pedrianes Martín & Pedro L. de Pablos Velasco. (2010) Seguridad y tolerabilidad de los antidiabéticos orales en el tratamiento de la diabetes mellitus tipo 2. Medicina Clínica 135, pages 20-26.
Crossref
Crossref
E. Sebokova, A. Bénardeau, U. Sprecher, S. Sewing, L. Tobalina & C. Migliorini. (2010) Taspoglutide, a novel human once-weekly analogue of glucagon-like peptide-1, improves glucose homeostasis and body weight in the Zucker diabetic fatty rat. Diabetes, Obesity and Metabolism 12:8, pages 674-682.
Crossref
Crossref
Louis Kuritzky. (2010) Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity. The American Journal of the Medical Sciences 340:2, pages 133-143.
Crossref
Crossref
Chidambarann SudhakaranMaryam FathimaRanjit Mohan AnjanaRanjit Unnikrishnan IViswanathan Mohan. (2010) Effectiveness of Exenatide in Asian Indians in a Clinical Care Setting. Diabetes Technology & Therapeutics 12:8, pages 613-618.
Crossref
Crossref
Y. Iwamoto, N. Tajima, T. Kadowaki, K. Nonaka, T. Taniguchi, M. Nishii, J. C. Arjona Ferreira & J. M. Amatruda. (2010) Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes, Obesity and Metabolism 12:7, pages 613-622.
Crossref
Crossref
Mark F. McCarty. (2010) Dietary saturate/unsaturate ratio as a determinant of adiposity. Medical Hypotheses 75:1, pages 14-16.
Crossref
Crossref
Jayashree S. Todkar, Shashank S. Shah, Poonam S. Shah & Jayashri Gangwani. (2010) Long-term effects of laparoscopic sleeve gastrectomy in morbidly obese subjects with type 2 diabetes mellitus. Surgery for Obesity and Related Diseases 6:2, pages 142-145.
Crossref
Crossref
Dominik Rachoń & Helena Teede. (2010) Ovarian function and obesity—Interrelationship, impact on women's reproductive lifespan and treatment options. Molecular and Cellular Endocrinology 316:2, pages 172-179.
Crossref
Crossref
T. Vilsbøll, J. Rosenstock, H. Yki‐Järvinen, W. T. Cefalu, Y. Chen, E. Luo, B. Musser, P. J. Andryuk, Y. Ling, K. D. Kaufman, J. M. Amatruda, S. S. Engel & L. Katz. (2009) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:2, pages 167-177.
Crossref
Crossref
Vasiliki Valla. (2010) Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps. Experimental Diabetes Research 2010, pages 1-14.
Crossref
Crossref
Christian Hölscher. 2010. Incretins and Insulin Secretion. Incretins and Insulin Secretion
331
354
.
Michael Freemark. 2010. Pediatric Obesity. Pediatric Obesity
339
355
.
Samuel Grossman. (2012) Differentiating Incretin Therapies Based on Structure Activity, and Metabolism: Focus on Liraglutide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:12P2.
Crossref
Crossref
David J. Heal, Jane Gosden & Sharon L. Smith. (2009) Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. British Journal of Clinical Pharmacology 68:6, pages 861-874.
Crossref
Crossref
Arne Astrup, Stephan Rössner, Luc Van Gaal, Aila Rissanen, Leo Niskanen, Mazin Al Hakim, Jesper Madsen, Mads F Rasmussen & Michael EJ Lean. (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. The Lancet 374:9701, pages 1606-1616.
Crossref
Crossref
Per M. Hellström. (2009) GLP-1: Broadening the incretin concept to involve gut motility. Regulatory Peptides 156:1-3, pages 9-12.
Crossref
Crossref
Nichola J. DavisNora TomutaClyde SchechterCarmen R. IsasiC.J. Segal-IsaacsonDaniel SteinJoel ZonszeinJudith Wylie-Rosett. (2009) Comparative Study of the Effects of a 1-Year Dietary Intervention of a Low-Carbohydrate Diet Versus a Low-Fat Diet on Weight and Glycemic Control in Type 2 Diabetes. Diabetes Care 32:7, pages 1147-1152.
Crossref
Crossref